Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 110

Sort by

Sort Order Select

Journal Articles

Lisaftoclax (APG-2575) Demonstrates Activity and Safety When Given with Accelerated Ramp-up and then Combined with Acalabrutinib or Rituximab in Patients (pts) with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Including Those with Prior Exposure to Venetoclax

Blood (2024) 144 (Supplement 1): 4614.

https://doi.org/10.1182/blood-2024-207408

Published: 2024

Journal Articles

Early Mortality in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Sociodemographic and Economic Factors Contributing to the Disparity

Firas Baidoun, Ricardo D. Parrondo, Vivek Roy, Andre Fernandez, Caitlin Flott, Taimur Sher, Rami Manochakian, Asher A. Chanan-Khan, Sikander Ailawadhi

Blood (2024) 144 (Supplement 1): 4723.

https://doi.org/10.1182/blood-2024-206351

Published: 2024

Journal Articles

Multi-Omics DNA Methylation Analysis of MYD88 Wild-Type Waldenstrom Macroglobulinemia Reveals Potential Epigenetic Influence on Oncogenic Pathways

Blood (2024) 144 (Supplement 1): 6201.

https://doi.org/10.1182/blood-2024-205509

Published: 2024

Journal Articles

Disparities in Multiple Myeloma (MM): Race/Ethnicity-Specific Sociodemographic and Economic Factors That May Drive Patient Decisions to Refuse Treatment

Firas Baidoun, Vivek Roy, Ricardo D. Parrondo, Andre Fernandez, Caitlin Flott, Taimur Sher, Rami Manochakian, Asher A. Chanan-Khan, Sikander Ailawadhi

Blood (2024) 144 (Supplement 1): 3790.

https://doi.org/10.1182/blood-2024-206308

Published: 2024

Journal Articles

Real World Outcomes with Venetoclax (Ven)-Based Therapies in Patients with Heavily Pretreated Relapsed/Refractory Multiple Myeloma (RRMM): A Mayo Clinic Comprehensive Cancer Center (MCCC) Experience

Blood (2024) 144 (Supplement 1): 1981.

https://doi.org/10.1182/blood-2024-208294

Published: 2024

Journal Articles

Lisaftoclax (APG-2575) Combined with Novel Therapeutic Regimens in Patients (pts) with Relapsed or Refractory Multiple Myeloma (R/R MM) or Immunoglobulin Light-Chain (AL) Amyloidosis

Sikander Ailawadhi, Asher A. Chanan-Khan, Jack Khouri, Costas K. Yannakou, Zi Chen, Yanyan Wang, Huanshan Guo, Hengbang Wang, Mingyu Li, Mohammad Ahmad, Dajun Yang, Yifan Zhai

Blood (2024) 144 (Supplement 1): 1022.

https://doi.org/10.1182/blood-2024-202713

Published: 2024

Journal Articles

Patient Awareness of CAR-T and Bispecific Antibody Treatments for Multiple Myeloma: Real-World Learnings and Disparities

Yaw Adu, Saurav Das, Dhaani Ailawadhi, Andre Fernandez, Ricardo Parrondo, Vivek Roy, Taimur Sher, Sean O'Connell, Ahsan Rasheed, Asher A Chanan- Khan, Sikander Ailawadhi

Blood (2023) 142 (Supplement 1): 2418.

https://doi.org/10.1182/blood-2023-189642

Published: 2023

Journal Articles

First Report on the Effects of Lisaftoclax (APG-2575) in Combination with Novel Therapeutic Regimens in Patients with Relapsed or Refractory Multiple Myeloma (R/R MM) or Immunoglobulin Light-Chain (Amyloid Light-Chain [AL]) Amyloidosis

Sikander Ailawadhi, Asher A. Chanan-Khan, Costas K. Yannakou, Simon Gibbs, Jack Khouri, Zi Chen, Huanshan Guo, Mingyu Li, Mohammad Ahmad, Cunlin Wang, Dajun Yang, Yifan Zhai

Blood (2023) 142 (Supplement 1): 2016.

https://doi.org/10.1182/blood-2023-188122

Published: 2023

Journal Articles

Racial Disparities and Their Impact on Knowledge, Behavioral Patterns, and Preferences Towards Participation in Clinical Trials Among Cancer Patients

Meghna Ailawadhi, MD, Mays F Abdulazeez, MBBS, Leyla Bojanini Molina, MD, Victoria R. Alegria, Taimur Sher, MD, Vivek Roy, MD, Rami Manochakian, MD, Aneel Paulus, MD, Asher A. Chanan-Khan, MD, Sikander Ailawadhi

Blood (2020) 136 (Supplement 1): 39–40.

https://doi.org/10.1182/blood-2020-140390

Published: 2020

Journal Articles

Efficacy of Daratumumab (Dara)-Based Regimens for the Treatment of Plasma Cell Leukemia (PCL)

Ricardo Parrondo, MD, Muhamad Alhaj Moustafa, MD, Craig B. Reeder, MD, Taimur Sher, MD, Vivek Roy, MD, Rahma M Warsame, MD, Victoria R. Alegria, Wilson I Gonsalves, MD, Prashant Kapoor, MD, David Dingli, MD PhD, Suzanne R. Hayman, MD, Asher A. Chanan-Khan, MD, Sikander Ailawadhi

Blood (2020) 136 (Supplement 1): 29–30.

https://doi.org/10.1182/blood-2020-139559

Published: 2020

Journal Articles

Daratumumab Plus Lenalidomide and Dexamethasone (DRd) Compared to Daratumumab Plus Pomalidomide and Dexamethasone (DPd) in Relapsed Lenalidomide-Exposed or Refractory Multiple Myeloma (MM) Patients: The Mayo Clinic Experience

Muhamad Alhaj Moustafa, MD, Ricardo Parrondo, MD, Mays F Abdulazeez, MBBS, Vivek Roy, MD, Taimur Sher, MD, Victoria R. Alegria, Rahma M Warsame, MD, Jeremy Larsen, Wilson I Gonsalves, MD, Taxiarchis Kourelis, MD, Prashant Kapoor, MD, Rafael Fonseca, MD, Francis K. Buadi, MB, CHB, David Dingli, MD PhD, Suzanne R. Hayman, MD, Craig B. Reeder, MD, Arshi Agrawal, Asher A. Chanan-Khan, MD, Sikander Ailawadhi

Blood (2020) 136 (Supplement 1): 1–2.

https://doi.org/10.1182/blood-2020-139929

Published: 2020

Journal Articles

Open Label, Multicenter, Dose-Escalation/ Expansion Phase Ib Study to Evaluate Safety and Activity of BET Inhibitor RO6870810 (RO), Given As Monotherapy to Patients (pts) with Advanced Multiple Myeloma

Karthik Ramasamy, Ajay Nooka, MDMPH, Hang Quach, MDFRACP,FRCPA,MBBS, Myo Htut, MD, Rakesh Popat, Michaela Liedtke, MD, Sascha A Tuchman, MD, Jacob P. Laubach, MD, Cristina Gasparetto, MD, Asher A. Chanan-Khan, MD, Mark Hertzberg, MBBS PhDFRACP FRCPA, Mark Demario, MD MPH, Eveline Nueesch, PhD, Evelyne Chesne, PhD, Izolda Franjkovic, PhD, Katharina Lechner, Martin Kornacker, MD, Hearn Jay Cho, MD PhD

Blood (2020) 136 (Supplement 1): 12–14.

https://doi.org/10.1182/blood-2020-136392

Published: 2020

Journal Articles

Disparities and Their Impact on the Adoption of Health Information Technology (HIT) in Minority Cancer Patients and Caregivers

Sikander Ailawadhi, MD, Meghna Ailawadhi, MD, Srilekha Bodepudi, Mays F Abdulazeez, BMSC, Zan Tahir Shareef, Ashna Grover, Maria J Fernandez, Winston Tan, MD, Victoria R. Alegria, Taimur Sher, MD, Vivek Roy, MD, Rami Manochakian, MD, Aneel Paulus, MD, Asher A. Chanan-Khan, MD

Blood (2019) 134 (Supplement_1): 411.

https://doi.org/10.1182/blood-2019-125722

Published: 2019

Journal Articles

Impact of Anti-CD19 CAR-T Axicabtagene Ciloleucel on Vaccine Titers of DTaP and MMR

Zaid Abdel Rahman, MD, Nicole Gannon, PA-C, Megan Melody, MD, Paul Muniz, RN, Ernesto Ayala, MD, Vivek Roy, MD, Lisa Brumble, Sikander Ailawadhi, MD, Taimur Sher, MD, James M. Foran, MD, Hemant S. Murthy, MD, Han W. Tun, MD, Candido E. Rivera, MD, Asher A. Chanan-Khan, MD, Abba C. Zubair, MD PhD, Mohamed A Kharfan-Dabaja, MDMBA

Blood (2019) 134 (Supplement_1): 5610.

https://doi.org/10.1182/blood-2019-122067

Published: 2019

Journal Articles

A Population-Based Analysis of Predictors of Survival and Trends in Outcomes of Elderly Patients with Multiple Myeloma (MM)

Vivek Kumar, MD, M.B.,B.S., Meghna Ailawadhi, MD, Mays F Abdulazeez, MBBS, Suman Biswas, MD, Sri Lekha Bodepudi, Leyla Bojanini, MD, Vivek Roy, MD, Taimur Sher, MD, Victoria R. Alegria, Rami Manochakian, MD, Aneel Paulus, MD, Asher A. Chanan-Khan, MD, Sikander Ailawadhi, MD

Blood (2019) 134 (Supplement_1): 4779.

https://doi.org/10.1182/blood-2019-125156

Published: 2019

Journal Articles

Trends in Early Mortality from Multiple Myeloma (MM): A Population-Based Analysis

Vivek Kumar, MD, M.B.,B.S., Mays F Abdulazeez, BMSC, Suman Biswas, MD, Sri Lekha Bodepudi, Vivek Roy, MD, Taimur Sher, MD, Meghna Ailawadhi, MD, Victoria R. Alegria, Aneel Paulus, MD, Salman Ahmed, MD, Prachi Jani, MD, Asher A. Chanan-Khan, MD, Sikander Ailawadhi, MD

Blood (2019) 134 (Supplement_1): 71.

https://doi.org/10.1182/blood-2019-124799

Published: 2019

Journal Articles

A Randomized Phase 2 Study Comparing Acalabrutinib with or without Obinutuzumab in the Treatment of Early Stage High Risk Patients with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Blood (2019) 134 (Supplement_1): 4306.

https://doi.org/10.1182/blood-2019-123824

Published: 2019

Journal Articles

Preliminary Safety and Anti-Tumor Activity of XmAb13676, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia

Krish Patel, MD, Jean-Marie Michot, MD, Asher A. Chanan-Khan, MD, Gilles A. Salles, MD PhD, Guillaume Cartron, MD PhD, Frederic Peyrade, MD, Reda Bouabdallah, Erin G. Reid, MD MS, Sheeba K. Thomas, MD, William G. Wierda, MD PhD, David Liebowitz, MD, John M. Pagel, MD PhD DSc, Vincent Ribrag, MD, M. Wayne Saville, MD, Chelsea M. Johnson, BSN, Thomas Ly, PhD, Tycel J. Phillips, MD

Blood (2019) 134 (Supplement_1): 4079.

https://doi.org/10.1182/blood-2019-128564

Published: 2019

Journal Articles

Phase 2 Trial of Ixazomib, Cyclophosphamide and Dexamethasone in Relapsed Multiple Myeloma

Blood (2019) 134 (Supplement_1): 1904.

https://doi.org/10.1182/blood-2019-131478

Published: 2019

Journal Articles

Primary Analysis of Anti-CD19 Tafasitamab (MOR208) Treatment in Combination with Idelalisib or Venetoclax in R/R CLL Patients Who Failed Prior BTK Inhibitor Therapy (COSMOS Trial)

Blood (2019) 134 (Supplement_1): 1754.

https://doi.org/10.1182/blood-2019-128388

Published: 2019

NARROW

Lisaftoclax (APG-2575) Demonstrates Activity and Safety When Given with Accelerated Ramp-up and then Combined with Acalabrutinib or Rituximab in Patients (pts) with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Including Those with Prior Exposure to Venetoclax

Early Mortality in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Sociodemographic and Economic Factors Contributing to the Disparity

Multi-Omics DNA Methylation Analysis of MYD88 Wild-Type Waldenstrom Macroglobulinemia Reveals Potential Epigenetic Influence on Oncogenic Pathways

Disparities in Multiple Myeloma (MM): Race/Ethnicity-Specific Sociodemographic and Economic Factors That May Drive Patient Decisions to Refuse Treatment

Real World Outcomes with Venetoclax (Ven)-Based Therapies in Patients with Heavily Pretreated Relapsed/Refractory Multiple Myeloma (RRMM): A Mayo Clinic Comprehensive Cancer Center (MCCC) Experience

Lisaftoclax (APG-2575) Combined with Novel Therapeutic Regimens in Patients (pts) with Relapsed or Refractory Multiple Myeloma (R/R MM) or Immunoglobulin Light-Chain (AL) Amyloidosis

Patient Awareness of CAR-T and Bispecific Antibody Treatments for Multiple Myeloma: Real-World Learnings and Disparities

First Report on the Effects of Lisaftoclax (APG-2575) in Combination with Novel Therapeutic Regimens in Patients with Relapsed or Refractory Multiple Myeloma (R/R MM) or Immunoglobulin Light-Chain (Amyloid Light-Chain [AL]) Amyloidosis

Racial Disparities and Their Impact on Knowledge, Behavioral Patterns, and Preferences Towards Participation in Clinical Trials Among Cancer Patients

Efficacy of Daratumumab (Dara)-Based Regimens for the Treatment of Plasma Cell Leukemia (PCL)

Daratumumab Plus Lenalidomide and Dexamethasone (DRd) Compared to Daratumumab Plus Pomalidomide and Dexamethasone (DPd) in Relapsed Lenalidomide-Exposed or Refractory Multiple Myeloma (MM) Patients: The Mayo Clinic Experience

Open Label, Multicenter, Dose-Escalation/ Expansion Phase Ib Study to Evaluate Safety and Activity of BET Inhibitor RO6870810 (RO), Given As Monotherapy to Patients (pts) with Advanced Multiple Myeloma

Disparities and Their Impact on the Adoption of Health Information Technology (HIT) in Minority Cancer Patients and Caregivers

Impact of Anti-CD19 CAR-T Axicabtagene Ciloleucel on Vaccine Titers of DTaP and MMR

A Population-Based Analysis of Predictors of Survival and Trends in Outcomes of Elderly Patients with Multiple Myeloma (MM)

Trends in Early Mortality from Multiple Myeloma (MM): A Population-Based Analysis

A Randomized Phase 2 Study Comparing Acalabrutinib with or without Obinutuzumab in the Treatment of Early Stage High Risk Patients with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Preliminary Safety and Anti-Tumor Activity of XmAb13676, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia

Phase 2 Trial of Ixazomib, Cyclophosphamide and Dexamethasone in Relapsed Multiple Myeloma

Primary Analysis of Anti-CD19 Tafasitamab (MOR208) Treatment in Combination with Idelalisib or Venetoclax in R/R CLL Patients Who Failed Prior BTK Inhibitor Therapy (COSMOS Trial)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only